Eris Lifesciences Reports 39% Increase in Q2 Net Profit to ₹187 Crore

NEW DELHI — Eris Lifesciences Ltd on Monday reported a 39.16 per cent rise in its consolidated net profit to ₹187.14 crore for the September quarter. The company had posted a net profit of ₹134.47 crore during the corresponding period of the previous fiscal year, according to its regulatory filing.

Total revenue from operations for the second quarter stood at ₹892.37 crore, marking an increase from ₹792.41 crore recorded in the year-ago period. Meanwhile, total expenses for the quarter under review increased to ₹702.86 crore, compared with ₹622.83 crore reported in the same period a year prior.

Commenting on the performance, Amit Bakshi, Chairman and Managing Director of Eris Lifesciences, said in a press statement that the domestic branded formulations business delivered a 14 per cent revenue growth in Q2. He noted that the company's major therapies continued to outgrow the broader market.

Bakshi highlighted that the diabetes segment strengthened following recent insulin and semaglutide product launches, registering a growth of 18.5 per cent against a market growth rate of 16.1 per cent. Additionally, he stated that the company's in-house developed recombinant Semaglutide has received approval to conduct Phase 1 and Phase 3 clinical trials.

On the stock exchanges, shares of Eris Lifesciences settled 0.37 per cent lower at ₹1,093.60 apiece on the Bombay Stock Exchange (BSE) on Monday.

"The financial performance of Eris Lifesciences reflects steady growth driven by core domestic operations and targeted product expansion in key therapeutic segments like diabetes. Companies focusing on in-house development and regulatory advancements for specialized treatments are well-positioned to scale effectively within the competitive healthcare market. Sustaining revenue growth while managing operational expenses will remain critical for long-term value creation in the pharmaceutical sector." — Dr. Shishir Gupta, Founder & CEO, StartupLanes